Aurinia Pharmaceuticals

(NASDAQ) AUPH

Current Price$15.23

Market Cap$2.03B

Since IPO (2012)+643%

5 Year+50%

1 Year+88%

1 Month-4%

Aurinia Pharmaceuticals Financials at a Glance

Market Cap

$2.03B

Revenue (TTM)

$298.30M

Net Income (TTM)

$298.21M

EPS (TTM)

$2.16

P/E Ratio

7.04

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$15.23

Volume

19,929

Open

$15.13

Price

$15.23

Volume

19,929

Open

$15.13

Previous Close

$15.23

Daily Range

$14.81 - $15.44

52-Week Range

$7.29 - $16.88

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$15.23

Volume

19,929

Open

$15.13

Previous Close

$15.23

Daily Range

$14.81 - $15.44

52-Week Range

$7.29 - $16.88

AUPH News

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?

Jonathan PoncianoDec 2, 2025

Page 1

AUPH: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aurinia Pharmaceuticals

Industry

Biotechnology

Sector

Health Care

Employees

128

CEO

Kevin C. Tang

Website

www.auriniapharma.com

Headquarters

Edmonton, BC V8Z 7X8, CA

AUPH Financials

Key Financial Metrics (TTM)

Gross Margin

90%

Operating Margin

42%

Net Income Margin

100%

Return on Equity

65%

Return on Capital

20%

Return on Assets

41%

Earnings Yield

14.20%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.03B

Shares Outstanding

132.97M

Volume

19.93K

Avg. Volume

1.10M

Financials (TTM)

Gross Profit

$250.39M

Operating Income

$104.91M

EBITDA

$127.76M

Operating Cash Flow

$135.66M

Capital Expenditure

$252.00K

Free Cash Flow

$135.41M

Cash & ST Invst.

$398.00M

Total Debt

$74.81M

Aurinia Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$77.70M

+24.4%

Gross Profit

$71.20M

+32.1%

Gross Margin

91.63%

N/A

Market Cap

$2.03B

N/A

Market Cap/Employee

$15.58M

N/A

Employees

130

N/A

Net Income

$34.35M

+47.2%

EBITDA

$49.75M

+64.4%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$310.14M

+32.0%

Accounts Receivable

$49.17M

+21.9%

Inventory

$46.41M

+0.5%

Long Term Debt

$50.50M

-19.0%

Short Term Debt

$18.14M

+16.7%

Return on Assets

41.19%

N/A

Return on Invested Capital

19.53%

N/A

Free Cash Flow

$32.52M

+2434.8%

Operating Cash Flow

$32.56M

+2404.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

STOKStoke Therapeutics, Inc.

STOKStoke Therapeutics, Inc.$32.89+0.30%

HRMYHarmony Biosciences Holdings, Inc.

HRMYHarmony Biosciences Holdings, Inc.$30.99-1.37%

CLDXCelldex Therapeutics, Inc.

CLDXCelldex Therapeutics, Inc.$33.97+1.95%

NUVBNuvation Bio Inc.

NUVBNuvation Bio Inc.$4.79-0.42%

ABCLAbCellera Biologics Inc.

ABCLAbCellera Biologics Inc.$5.24+8.71%

IMCRImmunocore Holdings plc

IMCRImmunocore Holdings plc$29.58-3.40%

VERAVera Therapeutics, Inc.

VERAVera Therapeutics, Inc.$36.19+0.86%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

RXTRackspace Technology

RXTRackspace Technology$5.49+0.56%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.28+0.07%

POETPoet Technologies

POETPoet Technologies$10.95+0.14%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.57-0.07%

NVDANvidia

NVDANvidia$215.20+0.02%

SOFISoFi Technologies

SOFISoFi Technologies$15.75-0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.35+0.01%

Questions About AUPH

What is the current price of Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals is trading at $15.23 per share.

What is the 52-week range for Aurinia Pharmaceuticals?

Over the past 52 weeks, Aurinia Pharmaceuticals has traded between $7.29 and $16.88.

How much debt does Aurinia Pharmaceuticals have?

As of the most recent reporting period, Aurinia Pharmaceuticals reported total debt of $68.64M.

How much cash does Aurinia Pharmaceuticals have on hand?

Aurinia Pharmaceuticals reported $41.01M in cash and cash equivalents in its most recent financial results.

What is Aurinia Pharmaceuticals’s dividend yield?

Aurinia Pharmaceuticals does not currently have a dividend yield.

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Financials at a Glance

AUPH News

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?

Aurinia (AUPH) Q2 Revenue Jumps 22%

Why Aurinia Pharmaceuticals Stock Is Slumping Today

Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday

Why Aurinia Pharmaceuticals Stock Is Glowing Green Today

Why Shares of Aurinia Pharmaceuticals Soared This Week

Why Aurinia Pharmaceuticals Stock Briefly Spiked Today

Why Aurinia Pharmaceuticals Stock Is Sliding Today

AUPH: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Aurinia Pharmaceuticals

AUPH Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Aurinia Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AUPH

What is the current price of Aurinia Pharmaceuticals?

What is the 52-week range for Aurinia Pharmaceuticals?

How much debt does Aurinia Pharmaceuticals have?

How much cash does Aurinia Pharmaceuticals have on hand?

What is Aurinia Pharmaceuticals’s dividend yield?

Premium Investing Services